Lineage Cell Therapeutics, Inc. (LCTX) Return on equity 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-142.6%FY2025 · since FY2016: 28.5% → -142.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -142.6% | -118.9 pp |
| FY2024 | -23.7% | +10.1 pp |
| FY2023 | -33.9% | +1.9 pp |
| FY2022 | -35.8% | +10.8 pp |
| FY2021 | -46.6% | -25.2 pp |
| FY2020 | -21.5% | -11.1 pp |
| FY2019 | -10.4% | +39.5 pp |
| FY2018 | -49.9% | -37.6 pp |
| FY2017 | -12.3% | -40.8 pp |
| FY2016 | 28.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More LCTX financial trends
LCTX RevenueLCTX Net incomeLCTX Net marginLCTX Gross profitLCTX Gross marginLCTX Operating incomeLCTX Operating marginLCTX Operating cash flowLCTX Free cash flowLCTX Capital expendituresLCTX Stock buybacksLCTX Dividends paidLCTX Total assetsLCTX Total liabilitiesLCTX Shareholders’ equityLCTX overview →